Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

AACR 2009: Frequent JAK Mutations in Pediatric Acute Lymphoblastic Leukemia (ALL) with Poor Outcome: A New Therapeutic Target in Resistant Disease

AACR 2009

18 - 22 Apr 2009

Published: 30 Apr 2009

Views: 14792

Rating:

Save

Dr Charles Mullighan - Department of Pathology, St Jude Children's Research Hospital

Charles Mullighan, M.B.B.S. (Hons), M.Sc., M.D., assistant member, department of pathology, St. Jude Children’s Research Hospital presents at the 2009 AACR conference in Denver: Frequent JAK Mutations in Pediatric Acute Lymphoblastic Leukemia (ALL) with Poor Outcome: A New Therapeutic Target in Resistant Disease

Related Videos

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and...

Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects ( Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal )

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma...

Dr Jonathan Friedberg - University of Rochester, Rochester, USA

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma treated with rituximab therapy ( Dr Jonathan Friedberg - University of Rochester, Rochester, USA )

Ide-cell enhances health-related quality of life for refractory multiple myeloma

Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium

$Ide-cell enhances health-related quality of life for refractory multiple myeloma ( Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium )$

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria...

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B...

Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany

Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B-cell lymphoma ( Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany )

Ponatinib is superior to imatinib in combination with chemotherapy for newly...

Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA

Ponatinib is superior to imatinib in combination with chemotherapy for newly diagnosed Ph+ ALL ( Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

The evolving paradigm in management of Multiple Myeloma

D Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

The evolving paradigm in management of Multiple Myeloma ( D Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )

More from ecancer